Skip to main content
. 2015 Mar 13;6(11):9313–9326. doi: 10.18632/oncotarget.3220

Figure 4. Knockdown of CD44 by lentiviral shRNA increased the paclitaxel sensitivity of ovarian cancer cells.

Figure 4

Panel (A) status of OVCAR8, OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, and OVCAR8CD44 shRNA cells that differed between representative concentrations of paclitaxel (0 μM and 0.006 μM). Panel (B) MTT assay showing cell viability of the above mention four cell lines with different concentrations of paclitaxel. The MTT assay was conducted in triplicate.